Healthcare Sector Review: Winning and Losing Stocks on Nov 1st

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Wall St. Watchdog reveals information about today’s action in the Healthcare (NYSE:XLV) sector:

Gainers (% price change)

  • Neurocrine Biosciences (NASDAQ:NBIX): The shares closed at $7.28, up $1.02, or 16.29%, on the day. Its market capitalization is $402.14 million. About the company: Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, Alzheimer’s disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.
  • Akorn, Inc. (NASDAQ:AKRX): The shares closed at $9.89, up $0.9, or 10.01%, on the day. Its market capitalization is $936.01 million. About the company: Akorn, Inc. develops, manufactures, and markets ophthalmic and injectable pharmaceutical products. The Company sells various diagnostic and therapeutic pharmaceutical products focused primarily on ophthalmology, anesthesia, antidotes, and rheumatology. Akorn also markets ophthalmic surgical instruments and other supplies, and provides contract manufacturing for third parties.
  • Pharmasset, Inc. (NASDAQ:VRUS): The shares closed at $76.99, up $6.59, or 9.36%, on the day. Its market capitalization is $5.81 billion. About the company: Pharmasset, Inc. is a pharmaceutical company. The Company develops oral therapeutics for the human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV).
  • NPS Pharmaceuticals, Inc. (NASDAQ:NPSP): The shares closed at $5.50, up $0.33, or 6.38%, on the day. Its market capitalization is $473.21 million. About the company: NPS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs.
  • (): The shares closed at $53.60, up $3.19, or 6.33%, on the day. Its market capitalization is $132.25 million.

Losers (% price change)

  • Exelixis, Inc. (NASDAQ:EXEL): The shares closed at $4.62, down $3.11, or 40.23%, on the day. Its market capitalization is $595.86 million. About the company: Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.
  • Amedisys, Inc. (NASDAQ:AMED): The shares closed at $10.06, down $3.07, or 23.38%, on the day. Its market capitalization is $294.35 million. About the company: Amedisys, Inc. is a multi-regional provider of alternate-site health care services. The Company offers home health care nursing, home infusion therapy, and ambulatory surgery centers. Amedisys operates offices within a network of subsidiaries in the southern and southeastern United States.
  • Almost Family, Inc. (NASDAQ:AFAM): The shares closed at $15.96, down $2.68, or 14.38%, on the day. Its market capitalization is $149.52 million. About the company: Almost Family, Inc. provides adult day health services to older and special needs adults as an alternative to nursing home placement. The Company also operates a visiting nurse service.
  • Bio-Reference (NASDAQ:BRLI): The shares closed at $17.60, down $2.44, or 12.18%, on the day. Its market capitalization is $491.92 million. About the company: Bio-Reference Laboratories, Inc. operates an independent clinical laboratory in the Northeast United States. The Company’s laboratory has specialty capability in the areas of genomics, oncology, correctional health, and complimentary medicine. Bio-Reference also offers information solutions for reducing healthcare costs and improving quality performance.
  • DUSA Pharmaceuticals, Inc (NASDAQ:DUSA): The shares closed at $4.06, down $0.44, or 9.78%, on the day. Its market capitalization is $100.08 million. About the company: DUSA Pharmaceuticals, Inc. is a development stage pharmaceutical company that is researching and developing a light sensitive drug known as ALA in combination with light devices. The Company is seeking to market its Levulan photodynamic therapy to treat pre-cancerous skin lesions of the face and scalp.

(Note: Selected financial data are sourced from Google Finance. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More Articles About:
Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business